LIPOSOMAL GOLD COMPOUNDS\IMPROVED ANTIARTHRITIC THERAPY

Award Information
Agency:
Department of Health and Human Services
Amount:
$46,571.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1991
Phase:
Phase I
Agency Tracking Number:
16355
Solicitation Topic Code:
N/A
Small Business Information
Vestar, Inc
650 Cliffside Drive, San Dimas, CA, 91773
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Konigsberg, Paula J
 Principal Investigator
 (714) 394-4000
Business Contact
 1 R43 AR41094-01
Phone: () -
Research Institution
N/A
Abstract
CONJUGATED GOLD COMPOUNDS SUCH AS AUROTHIOMALATE, ARE ADMINISTERED IN PROGRESSIVE RHEUMATOID ARTHRITIS. AT PRESENT, ONLY THESE ANTIARTHRITICS ARREST THE PROGRESSION OF THE DISEASE. TREATMENT IS LIMITED BECAUSE SEVERE ORGAN TOXICITIES OCCUR IN 33% OF PATIENTS TAKING PARENTERAL OR ORAL GOLD COMPOUNDS. IT IS PROPOSED THAT AUROTHIOMALATE OR AUROTHIOGLUCOSE ENCAPSULATED INTO THE INTERNAL AQUEOUS SPACE OF UNILAMELLAR PHOSPHOLIPIDS VESICLES (LIPOSOMES) WOULD BE A MORE EFFECTIVE FORM OF THE DRUG BECAUSE TOXICITY WOULD BE REDUCED. IT IS FURTHER PROPOSED THAT THE DRUG WOULD BE DELIVERED TO LYMPHOCYTES FOUND IN THE SYNOVIUM AND INHIBIT THE PRODUCTION OF INFLAMMATORY MEDIATORS BY THESE CESS. THIS STUDY WILL INVOLVE THE PREPARATION OF GOLD COMPOUNDS INTO SMALL UNILAMELLAR VESICLES, EVALUATION OF THESE FORMULATIONS FOR STABILITY AND IN VITRO ACTIVITY, AND TESTING OF APPROPRIATE FORMULATIONS IN TYPE II COLLAGEN INDUCED ARTHRITIS MODEL IN MICE. DEVELOPMENT OF THIS DRUG DELIVERY SYSTEM WOULD EXTEND VESTAR'S TECHNOLOGY BASE BY THE DEVELOPMENT OF A LIPOSOME DRUG DELIVERY SYSTEM FOR WATER SOLUBLE ANTIINFLAMMATORY AGENTS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government